Home › Ovarian Cancer › Minnesota
Ovarian Cancer clinical trials in Minnesota
53 studies for Ovarian Cancer are looking for participants at sites in Minnesota.
Cities in Minnesota
- Rochester29 studies
- Minneapolis24 studies
- Saint Paul8 studies
- Duluth5 studies
- Brooklyn Park4 studies
- Plymouth4 studies
- Bloomington3 studies
The Vanguard Study: Testing a New Way to Screen for Cancer
- Minneapolis VA Medical Center, Minneapolis
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Oct 5, 2026 · NCT06995898Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Masonic Cancer Center, University of Minnesota, Minneapolis
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 5, 2026 · NCT06915025Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07001748Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Sanford Joe Lueken Cancer Center, Bemidji
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- and 12 more
RecruitingPhase 2
All ages · All sexes · Updated Oct 5, 2026 · NCT05564377A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Health Partners Frauenshuh Cancer Center, Saint Louis Park
- Health Partners Cancer Center at Regions Hospital, Saint Paul
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06172478A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- University Of Minnesota /ID# 277850, Minneapolis
RecruitingPhase 2
Ages 18 and older · Women · Updated Oct 1, 2026 · NCT07024784Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Mayo Clinic, Rochester
RecruitingObservational study
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05051722Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
- Mayo Clinic, Rochester
Recruiting
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05287451A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- University of Minnesota - Minneapolis /ID# 275718, Minneapolis
- Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 274780, Saint Louis Park
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT06890338A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0288 - Minnesota Oncology Hematology - Maplewood, Maplewood
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05128825Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Mayo Clinic Rochester, Rochester
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Mayo Clinic - Rochester, Rochester
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT03564340A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Mayo Clinic in Rochester, Minnesota, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213804A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Mayo Clinic - Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213791A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Mayo Rochester, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07109726A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Minnesota Oncology-Minneapolis, Minneapolis
RecruitingPhase 2
Ages 18 to 99 · Women · Updated Sep 15, 2026 · NCT07023627ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Mayo Clinic (Rochester), Rochester
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Minnesota Oncology Hematology (MNO) ( Site 8002), Maplewood
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06824467FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- University of Minnesota Masonic Cancer Center, Minneapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07216105Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- University of Minnesota, Minneapolis
RecruitingPhase 1
Ages 15 and older · All sexes · Updated Aug 25, 2026 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- University of Minnesota/Masonic Cancer Center, Minneapolis
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Minneapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Minnesota Oncology - Burnsville, Burnsville
- Cambridge Medical Center, Cambridge
- Minnesota Oncology Hematology PA-Chaska, Chaska
- and 26 more
Recruiting
Ages 35 to 50 · Women · Updated Aug 7, 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Riverwood Healthcare Center, Aitkin
- Essentia Health - Baxter Clinic, Baxter
- Sanford Joe Lueken Cancer Center, Bemidji
- and 48 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06580314A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- M Health Fairview University of Minnesota Medical Center, Minneapolis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Minnesota Oncology Hematology, Maplewood
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Minnesota Oncology Hematology, Maple Grove
- Mayo Clinic (Minnesota), Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- St. Luke's Hospital, Duluth
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 518, Minneapolis
RecruitingPhase 2
Ages 18 and older · Women · Updated Jul 16, 2026 · NCT06906341Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
- Mayo Clinic Methodist Campus, Rochester
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 14, 2026 · NCT05804370Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- University of Minnesota - Masonic Cancer Center, Minneapolis
- Mayo Clinic, Rochester
RecruitingPhase 2
Ages 18 and older · Women · Updated Jul 14, 2026 · NCT04606914CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
- The Mayo Clinic, Rochester
RecruitingPhase 1/2
Ages 18 to 75 · Women · Updated Jul 13, 2026 · NCT07322094UNTOLD Ovarian Cancer Unmet Needs Survey
- Masonic Cancer Center, Minneapolis
RecruitingObservational study
Ages 18 and older · Women · Updated Jul 8, 2026 · NCT07070726A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
- Mayo Clinic, Rochester
RecruitingPhase 1
Ages 18 and older · Women · Updated Jul 6, 2026 · NCT07226427Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Mayo Clinic in Rochester, Minnesota, Rochester
RecruitingPhase 1/2
Ages 18 to 90 · All sexes · Updated Jul 6, 2026 · NCT06710756A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Allina Health Cancer Institute - Mercy Hospital, Coon Rapids
- Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
- Allina Health Cancer Institute - United Hospital, Saint Paul
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT04389632Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Minnesota Oncology Hematology PA, Minneapolis
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 2, 2026 · NCT06819007A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Mayo Clinic - Rochester, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996Integrated Cancer Repository for Cancer Research
- Riverwood Healthcare Center, Aitkin
- Essentia Health-St. Joseph's Medical Center, Brainerd
- Essentia Health - Duluth Clinic, Duluth
- and 2 more
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- Mayo Clinic Rochester, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT06051695From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.